PE20040929A1 - Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas - Google Patents

Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas

Info

Publication number
PE20040929A1
PE20040929A1 PE2004000008A PE2004000008A PE20040929A1 PE 20040929 A1 PE20040929 A1 PE 20040929A1 PE 2004000008 A PE2004000008 A PE 2004000008A PE 2004000008 A PE2004000008 A PE 2004000008A PE 20040929 A1 PE20040929 A1 PE 20040929A1
Authority
PE
Peru
Prior art keywords
methyl
pyrrol
cycloalkyl
carboxyl
phenyl
Prior art date
Application number
PE2004000008A
Other languages
English (en)
Inventor
Werner Englberger
Hagen-Heinrich Hennies
Corinna Sundermann
Babette-Yvonne Koegel
Beatrix Merla
Utz-Peter Jagusch
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20040929A1 publication Critical patent/PE20040929A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

SE REFIERE A AMIDAS DE ACIDO 5-AMINOMETIL-1H-PIRROL-2-CARBOXILICO SUBSTITUIDAS DE FORMULA I DONDE R1 ES H, ALQUILO, CICLOALQUILO CON HETEROATOMO COMO MIEMBRO DEL ANILLO, ARILO, HETEROARILO, ENTRE OTROS; R2 ES ALQUILO, CICLOALQUILO CON HETEROATOMO COMO MIEMBRO DEL ANILLO, ARILO, ENTRE OTROS; R1 Y R2 JUNTO CON EL N AL QUE ESTAN UNIDOS FORMAN UN CICLOALQUILO SATURADO O INSATURADO; R3 ES ARILO, HETEROARILO, ENTRE OTROS; R4 Y R5 SON H, ALQUILO, CICLOALQUILO ENTRE OTROS; R4 Y R5 JUNTO A N FORMAN UN RESTO CICLOALQUILO SATURADO O INSATURADO, ENTRE OTROS; R6 ES ALQUILO, CICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS CICLOHEXILAMIDA DE ACIDO 5-[DIMETILAMINO-(4-FLUORO-FENIL)-METIL]-1-METIL-1H-PIRROL-2-CARBOXILICO, BUTILAMIDA DE ACIDO 5-[DIMETILAMINO(4-FLUORO-FENIL)-METIL]-1-METIL-1H-PIRROL-2-CARBOXILICO, {5-[DIMETILAMINO-(4-FLUORO-FENIL)-METIL]-1-METIL-1H-PIRROL-2-I}-PIRROLIDIN-1-IL-METANONA, CICLOHEXILAMIDA DE ACIDO 5-[DIMETILAMINO-(4-BROMO-FENIL)-METIL]-1-METIL-1H-PIRROL-2-CARBOXILICO, ENTRE OTROS. SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION Y COMPOSICIONES. LOS COMPUESTOS MENCIONADOS TIENEN ALTA AFINIDAD POR EL RECEPTOR OPIOIDE (ORL-1) Y SON UTILES PARA EL TRATAMIENTO DE DOLORES CRONICOS, AGUDOS, NEUROPATICOS
PE2004000008A 2002-12-20 2004-01-05 Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas PE20040929A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10261131A DE10261131A1 (de) 2002-12-20 2002-12-20 Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide

Publications (1)

Publication Number Publication Date
PE20040929A1 true PE20040929A1 (es) 2005-01-07

Family

ID=32404308

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000008A PE20040929A1 (es) 2002-12-20 2004-01-05 Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas

Country Status (9)

Country Link
US (1) US7229991B2 (es)
EP (1) EP1581490B1 (es)
AR (1) AR042521A1 (es)
AT (1) ATE496887T1 (es)
AU (1) AU2003294900A1 (es)
DE (2) DE10261131A1 (es)
ES (1) ES2356446T3 (es)
PE (1) PE20040929A1 (es)
WO (1) WO2004058707A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003291342A1 (en) * 2002-11-05 2004-06-07 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
CN101792417A (zh) 2003-06-17 2010-08-04 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
CN1809545A (zh) * 2003-06-20 2006-07-26 艾尼纳制药公司 N－苯基－哌嗪衍生物和预防或者治疗5HT2c受体相关疾病的方法
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
DE102004024772A1 (de) 2004-05-17 2005-12-22 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
SI1833473T1 (sl) * 2004-12-23 2010-01-29 Arena Pharm Inc Sestavki modulatorjev 5HT2C receptorjev in postopki uporabe
EP3034494A1 (en) * 2007-08-15 2016-06-22 President and Fellows of Harvard College Heterocyclic inhibitors of necroptosis
JP5491421B2 (ja) * 2008-03-04 2014-05-14 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ｈｔ２ｃアゴニストである（ｒ）−８−クロロ−１−メチル−２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピンに関連する中間体の調製のためのプロセス
KR20130112848A (ko) 2010-06-02 2013-10-14 아레나 파마슈티칼스, 인크. 5-ｈｔ2ｃ 수용체 아고니스트의 제조 방법
MX2013002422A (es) 2010-09-01 2013-05-17 Arena Pharm Inc Sales de lorcaserina con acidos opticamente activos.
CN103189360A (zh) 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的非吸湿性盐
SG188365A1 (en) 2010-09-01 2013-04-30 Arena Pharm Inc Administration of lorcaserin to individuals with renal impairment
EP3485878A1 (en) 2010-09-01 2019-05-22 Arena Pharmaceuticals, Inc. Modified-release dosage forms of 5-ht2c agonists useful for weight management
AU2012392187B2 (en) 2012-10-09 2018-07-12 Arena Pharmaceuticals, Inc. Method of weight management
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551571A (en) * 1967-05-19 1970-12-29 Endo Lab Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones
AU2001271631A1 (en) * 2000-06-30 2002-01-14 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl aminoacyl pyrrole compounds
DK1351950T3 (da) * 2000-12-20 2007-12-03 Ortho Mcneil Pharm Inc Isoquinolinylaroylpyrrolforbindelser ti behandling af lidelser i centralnervesystemet
US6849730B2 (en) * 2001-09-25 2005-02-01 North Carolina State University Methods of making porphyrins and related compounds with Lewis acids

Also Published As

Publication number Publication date
ES2356446T3 (es) 2011-04-08
ATE496887T1 (de) 2011-02-15
DE10261131A1 (de) 2004-07-01
US20050288342A1 (en) 2005-12-29
US7229991B2 (en) 2007-06-12
AU2003294900A1 (en) 2004-07-22
WO2004058707A1 (de) 2004-07-15
EP1581490A1 (de) 2005-10-05
DE50313444D1 (en) 2011-03-10
EP1581490B1 (de) 2011-01-26
AR042521A1 (es) 2005-06-22

Similar Documents

Publication Publication Date Title
PE20040929A1 (es) Amidas de acido 5-aminometil-1h-pirrol-2-carboxilico substituidas
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
AR077818A1 (es) Composiciones pesticidas
PE20071080A1 (es) Compuestos de pirimidinona biciclicos como inhibidores de la integrasa de hiv
EA200400953A1 (ru) Замещённые пиридиноны в качестве модуляторов map-киназы p38
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
PE20091444A1 (es) Derivados de isoxazolo-pirazina
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
EA201070872A1 (ru) Производные азабициклических карбоксамидов, их получение и их применение в терапии
PE20120911A1 (es) Derivados de prolina como inhibidores de catepsina
AR043015A1 (es) Compuestos moduladores de amida derivada de quinolina del receptor vanilloide vr1, composiciones farmaceuticas y veterinarias que los contienen y su uso en el tratamiento de enfermedades afectadas por la modulacion de dichos receptores
EA200400387A1 (ru) Азабициклические замещённые конденсированные гетероарильные соединения для лечения заболеваний
PE20070194A1 (es) Compuestos de pirazolina 4-sustituidos como moduladores de cb1
PE20080830A1 (es) Compuestos derivados de sulfonilo que modulan el receptor cb2
AR068054A1 (es) Compuestos de pirrolopirimidina
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20120533A1 (es) Inhibidores del virus de la hepatitis c
DOP2005000071A (es) "compuestos de metil-aril o heteroaril-amida sustituida"
PE20100144A1 (es) Compuestos quimicos 293
JP2018502148A5 (es)
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal